




European Lung
Cancer Conference

www.lungcancer2012.org

3rd EUROPEAN LUNG CANCER CONFERENCE

Program Book



Geneva
Switzerland

18-21 April 2012


Organizers



LET'S THINK

BOEHRINGER INGELHEIM
IS COMMITTED TO ONCOLOGY
AND ADVANCED RESEARCH IN
THE AREAS OF:

- ANGIOGENESIS INHIBITION
- SIGNAL TRANSDUCTION INHIBITION
- CELL-CYCLE KINASE INHIBITION



WWW.INONCOLOGY.COM

COPYRIGHT ©2010. BOEHRINGER INGELHEIM PHARMACEUTICALS INC
ALL RIGHTS RESERVED 201006179
ONCO124: JANUARY 2012

LET'S WORK
ONCOLOGY FROM BOEHRINGER INGELHEIM



WELCOME TO THE 3rd EUROPEAN LUNG CANCER CONFERENCE

On behalf of The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), it gives us great pleasure to welcome you to the 3rd European Lung Cancer Conference.

After two successful Conferences, the goal of the ELCC is still to provide a comprehensive overview of the most significant advances in lung cancer research and treatment and to deliver an outstanding program with the right balance of clinical relevance, which covers the entire spectrum of practice issues in lung cancer. Treatment must be approached by multiple specialists who aim to provide a personalized treatment strategy for every patient therefore there is a strong multidisciplinary influence in the program.

We trust that participants will benefit from the high value, scope and depth of the information on: tumor biology, pathology, prevention, early detection, epidemiology, tobacco control, imaging, staging, management-related issues and translational and clinical research, presented with the emphasis on interdisciplinary challenges and supported by clinical interpretations needed for application of recent studies.

A sincere thank you to the 2012 scientific committee, invited speakers, organizers and sponsors for their commitment to this Conference. We hope that you enjoy the meeting enough to join us again in 2014.

Bernward Passlick and Rolf A. Stahel
Scientific Committee Co-Chairs




Bernward Passlick




Rolf A. Stahel

14:30/ **INDIVIDUALIZED TREATMENT IN EARLY NSCLC**
16:00 *Chairs: A. Brunelli, Ancona, Italy
and S. Senan, Amsterdam, Netherlands* ROOM A&B

14:30 Functional operability: Lessons learned
A. Brunelli, Ancona, Italy

14:55 Surgical approaches beyond lobectomy
and pneumonectomy
A. D'Andrilli, Rome, Italy

15:20 What can radiotherapy provide beyond the standard?
D. De Ruyscher, Maastricht, Netherlands

15:45 Questions and Answers

14:30/ **PROFFERED PAPER SESSION**
16:00 **Translational research, Biology and Pathology**
Chairs: A. A. Adjei, Buffalo, NY, USA and TBC ROOM C

14:30 760 - FISH for detection of predictive ALK gene rearrangements in
histological non-small cell lung carcinoma specimens
S. Savic, Basel, Switzerland

14:40 770 - LACE-Bio: Validation of the prognostic role of tumor
lymphocytic infiltration in resectable non-small cell lung cancer
E. Brambilla, Grenoble, France

14:50 780 - Driver gene alterations in Chinese non-small cell lung cancer
patients, Y. Wu, Guangzhou, China

15:00 Invited Discussant, abstracts 760, 770 and 780
L. Bubendorf, Basel, Switzerland

15:15 790 - Ribonucleotide reductase subunit 2 (RRM2) predicts
shorter survival in resected stage I-III non-small cell lung
cancer (NSCLC) patients
M.G. Dal Bello, Genova, Italy

15:25 800 - Serum proteomic classifier for patients with advanced
non-small cell lung cancer (NSCLC) treated with erlotinib and
bevacizumab in first line: pooled analysis of phase II trials
SAKK19/05 and NTR528
O. Gautschi, Bern and Lucerne, Switzerland

15:35 810 - Upfront genomic testing for patients with non-small cell
lung cancer (NSCLC) receiving first-line platinum-based regimen:
preliminary result of the MSN study
D. Planchard, Villejuif, France

15:45 Invited Discussant, abstracts 790, 800 and 810
D. Gandara, Sacramento, CA, USA

14:30/16:00	PROFFERED PAPER SESSION Early stage and locally advanced NSCLC <i>Chairs: A. A. Adjei, Buffalo, NY, USA and TBC</i>	ROOM K
14:30	1320 - Should radiologically "solid" tumor be valid for limited resection in small-sized lung cancer? A. Hattori, Tokyo, Japan	
14:40	1330 - Lung cancer with scattered consolidation: New radiological independent category of peripheral lung cancer on thin-section computed tomography T. Matsunaga, Tokyo, Japan	
14:50	1340 - The size of consolidation on thin-section computed tomography is a better predictor of survival than the maximum tumor dimension in resectable lung cancer T. Maeyashiki, Tokyo, Japan	
15:00	Invited Discussant, abstracts 1320, 1330 and 1340 W. Klepetko, Vienna, Austria	
15:15	1350 - Stereotactic body radiotherapy (SBRT) using volumetric modulated arc therapy (VMAT) with flattening filter free (FFF) modality for medically inoperable early stage non-small cell lung cancer (NSCLC): A prospective single institutional experience P. Navarria, Rozzano, Italy	
15:25	1360 - Early response after 40 Gy to concurrent radiochemotherapy (RTCT) after induction chemotherapy strongly predicts complete response, time to progression and overall survival in locally advanced non-small cell lung cancer (NSCLC), Y. Vano, Nice, France	
15:35	1370 - Imaging early radiotherapy (RT)-induced changes of proliferation in patients with non-small cell lung cancer (NSCLC) using FLT-PET I. Trigonis, Manchester, UK	
15:45	Invited Discussant, abstracts 1350, 1360 and 1370 F. Mornex, Pierre Benite, France	
16:00	COFFEE BREAK	EXHIBITION
16:20/17:50	INDIVIDUALIZED TREATMENT OF ADVANCED NSCLC WITH AVAILABLE AGENTS <i>Chairs: M. Kris, New York, NY, USA and K. O'Byrne, Dublin, Ireland</i>	ROOM A&B
16:20	Chemotherapy K. O'Byrne, Dublin, Ireland	
16:40	EGFR, T.S. K. Mok, Hong Kong, China	
17:00	VEGF inhibitors M. Reck, Grosshansdorf, Germany	
17:20	ALK inhibitors F. Blackhall, Manchester, UK	
17:40	Questions and Answers	